Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27695097 | 0.80 | RAB9A (0.42) | FADS1NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL4149879 | 0.80 | MEN1 (0.59) | NPC1RAB9AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL482522 | 0.80 | HPGD (0.57) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL6805383 | 0.78 | MMP3 (0.56) | NPC1RAB9AALDH1A1KDM4EGAA | |
| SCHEMBL10532020 | 0.76 | DDX3X (0.44) | ALDH1A1GAAMAPT | |
| SCHEMBL6110708 | 0.76 | JAK2 (0.52) | NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL429187 | 0.75 | PTPN1 (0.48) | NPC1RAB9AKDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL7407843 | 0.75 | PTGS1 (0.60) | FADS1NPC1RAB9APTGS1ALDH1A1 | |
| SCHEMBL55828 | 0.74 | GAA (0.42) | NPC1ALDH1A1KDM4EHSD17B10GAA | |
| SCHEMBL11743614 | 0.74 | NPC1 (0.72) | FADS1NPC1RAB9APTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-11-19 | — | — | US | claimed |
| EP-2081933-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-29 | — | — | EP | claimed |
| WO-2008037477-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | claimed |
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-11-19 | — | — | US | disclosed |
| EP-2081933-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008037477-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| CN-1313439-C | Compounds and compositions for delivery of active agents | EMISPHERE TECH INC (US) | 2007-05-02 | — | — | CN | disclosed |
| CN-1315936-A | Compounds and compositions for delivery of active agents | EMISPHERE TECH INC (US) | 2001-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | ATR, ATM, CHEK1 | FADS1 1402/4885NPC1 1299/4885RAB9A 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.